AGIO Stock Analysis: Buy, Sell, or Hold?
AGIO - Agios Pharmaceuticals, Inc.
$29.92
0.49 (1.66%)
▲
5d:
+6.44%
30d:
-1.03%
90d:
+6.78%
BUY
MODERATE Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 07, 2026
Get Alerted When AGIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: AGIO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: AGIO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: AGIO is currently trading at $29.92, which is considered extended relative to its 30-day fair value range of $27.92 to $29.72.
Technical Outlook: Technically, AGIO is in a downtrend. Immediate support is located at $27.40, while resistance sits at $30.87.
Market Sentiment: AGIO has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $39.88 (+35.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AGIO is in a downtrend. Immediate support is located at $27.40, while resistance sits at $30.87.
Market Sentiment: AGIO has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $39.88 (+35.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$27.92 -
$29.72
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 35.5% below Wall St target ($39.88)
Fair Price Analysis
30-Day Fair Range
$27.92 -
$29.72
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$3.35
(11.2%)
Support & Resistance Levels
Support Level
$27.40
Resistance Level
$30.87
Current Trend
Downtrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.76
Wall Street Target
$39.88
(+35.5%)
Revenue Growth (YoY)
86.1%
Share & Embed Analysis
Last updated: March 30, 2026 10:08 AM ET
Data refreshes hourly during market hours. Next update: 11:08 AM
Data refreshes hourly during market hours. Next update: 11:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AGIO showing a specific setup today?
Insider Activity (6 Months)
1
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Krishnan Viswanadhan
SELL
2959 shares
2026-03-05
Tsveta Milanova
SELL
2872 shares
2026-01-05
Brian Goff
SELL
18703 shares
2025-12-30
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 59 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$873 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 57 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$224 | 61 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 59 HOLD |
